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Coronavirus disease 2019 (COVID-19) is likely to have long-term mental health effects on 
individuals who have recovered from COVID-19. Rightly, there is a global response for 
recognition and planning on how to deal with mental health problems for everyone 
impacted by the global pandemic. This does not just include COVID-19 patients but the 
general public and health care workers as well. There is also a need to understand the 
role of the virus itself in the pathophysiology of mental health disorders and longer-term 
mental health sequelae. Emerging evidence suggests that COVID-19 patients develop 
neurological symptoms such as headache, altered consciousness, and paraesthesia. 
Brain tissue oedema and partial neurodegeneration have also been observed in an autopsy. 
In addition, there are reports that the virus has the potential to cause nervous system 
damage. Together, these findings point to a possible role of the virus in the development 
of acute psychiatric symptoms and long-term neuropsychiatric sequelae of COVID-19. 
The brain pathologies associated with COVID-19 infection is likely to have a long-term 
impact on cognitive processes. Evidence from other viral respiratory infections, such as 
severe acute respiratory syndrome (SARS), suggests a potential development of psychiatric 
disorders, long-term neuropsychiatric disorders, and cognitive problems. In this paper, 
we will review and evaluate the available evidence of acute and possible long-term 
neuropsychiatric manifestations of COVID-19. We will discuss possible pathophysiological 
mechanisms and the implications this will have on preparing a long-term strategy to 
monitor and manage such patients.
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INTRODUCTION
Coronaviruses are single-stranded RNA viruses, which caused two well-known outbreaks: 
(1) severe acute respiratory syndrome (SARS) in 2002 and (2) Middle East respiratory 
syndromes (MERS) in 2012. Since December 2019, several cases of atypical pneumonia 
have been reported from Wuhan, China. A novel coronavirus was identified to be  the 
cause and was subsequently named by the WHO as: “severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2).” It is well known that coronaviruses affect the respiratory 
tract, with most patients experiencing only mild symptoms akin to the common cold (e.g., 
blocked/runny nose, headaches, sneezing, a raised temperature, loss of taste and smell, etc.) 
and the illness is self-limiting. However, if the virus reaches lower respiratory tract, in 
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vulnerable individuals such as new-born, elderly, and 
immunocompromised, it can cause severe illness such as 
pneumonia, bronchitis, exacerbation of asthma, chronic 
obstructive pulmonary disease (COPD), and acute respiratory 
syndrome (ARS), as seen in SARS, MERS, and now COVID-19 
(Desforges et  al., 2014; Raj et  al., 2014). Unfortunately, 
coronavirus is an opportunistic virus and can allude immune 
response, potentially spreading to cells other than the 
respiratory tract’s epithelial cells. Several coronaviruses have 
shown to be  neuro-invasive, including SARS and MERS 
(Gu et  al., 2005; Xu et  al., 2005; Arabi et  al., 2015).
As of the 28th of June 2020, SARS-CoV-2 has now infected 
over 10  million people worldwide (Dong et  al., 2020) and 
the pandemic continues to grow. The disease caused by 
SARS-CoV-2 is known as corona virus disease 2019 (COVID-
19), which manifests not just as a respiratory illness but 
also impacts the cardiovascular, renal, and the nervous system 
functions (Yuki et  al., 2020). It is known from previous 
pandemics, such as Spanish influenza and SARS, that there 
are not just acute effects of the viral infection but also long-
term sequelae due to disease itself as well as social effects 
due to governmental measures of containment such as 
quarantine, social distancing, and lockdown.
In this paper, we  aim to present an understanding of 
pathophysiology, possible effects of SARS-CoV-2 infection to 
the brain and its long-term neuropsychiatric and cognitive 
consequences. Understanding neuropsychiatric and cognitive 
consequences are important, as millions of individuals have 
been affected; many more are undetected, and the number 
of infections is still rising. If even a fraction of such individuals 
experience neuropsychiatric complications, the public health 
implications could be  considerable. Therefore, it is important 
to understand the neuropsychiatric and cognitive consequences 
of COVID-19. In this paper, we  will briefly outline how 
COVID-19 can affect the central nervous system (CNS), review 
emerging evidence of effects on CNS and explore the possible 
neuropsychiatric sequelae of the COVID-19 infection. We will 
discuss diverse neuropsychiatric and cognitive complications 
following COVID-19 infection, possibly affecting a large 
proportion of individuals previously suffering from COVID-
19. This, in turn, could lead to a potential increase in patients 
with psychiatric and cognitive problems. Understanding and 
assessing cognitive consequences following COVID-19 is 
important as it could be  used to estimate an individual’s 
capacity to work effectively, drive, manage finances, participate 
in daily family activities, or make informed decisions. 
Appropriate neuropsychological rehabilitation could be 
planned to remediate or compensate for cognitive deficits in 
COVID-19 survivors.
Neuropsychiatric consequences are neurological, psychiatric, 
and cognitive problems due to direct brain damage, disease, 
or indirect effects on the CNS via an immune response or 
medical therapy (Rogers et  al., 2020). The acute psychiatric 
manifestations of COVID-19 reported in surveys are increased 
stress, anxiety, and depression (Asmundson and Taylor, 2020). 
In the long-term, psychiatric presentations could also 
be affected by the outcome of their illness, stigma or memories, 
and amnesia associated with the critical care they receive 
(Jones et  al., 1998). Acute neurological symptoms such as 
headache, altered sensorium, acute cerebrovascular incidents, 
convulsions, and ataxia have been reported in more than 
a third of hospitalized patients (Mao et  al., 2020). Reports 
of acute cognitive complications such as attention and 
dysexecutive symptoms are also emerging (Rogers et  al., 
2020; Varatharaj et al., 2020). However, we can just speculate 
about the long-term neuropsychiatric and cognitive consequences 
of COVID-19.
PATHOPHYSIOLOGY OF 
NEUROPSYCHIATRIC AND COGNITIVE 
CONSEQUENCES OF COVID-19
SARS-CoV-2 is a novel virus and its pathophysiological 
mechanism on various physiological systems is yet to be  fully 
understood. However, a lot can be  learnt from other subtypes 
of coronaviruses. Coronaviruses primarily affect upper respiratory 
tracts, but they have been detected both in the brain and 
cerebrospinal fluids of the infected individuals (Bohmwald 
et  al., 2018). There are several mechanisms through which 
coronaviruses can damage the nervous system. These may 
include direct infection injury, virus entering through blood 
circulation pathway, neuronal pathway, hypoxic injury, immune 
injury, and via binding to the angiotensin-converting enzyme 
2 (ACE2). The neurotropic capacities of coronaviruses allow 
them to evade the immune response of the host and achieve 
latency. This makes them a potent factor to cause acute and 
late neurological effects. Although early indication shows that 
the expression of SARS-CoV-2  in the brain deviates slightly 
compared to SARS-CoV-1 and MERS expression, it is still a 
potential source for causing short and long-term neuropsychiatric 
and cognitive complications. For a detailed discussion of these 
mechanisms, please see Wu et al. (2020). The neuronal pathway 
via the olfactory nerve and role of ACE2 has been observed 
to be  the primary pathophysiological mechanisms contributing 
to neuropsychiatric and cognitive complications in COVID-19 
(Mirfazeli et  al., 2020; Pantelis et  al., 2020). This is mainly 
because coronaviruses affect the respiratory tract and can reach 
the ACE2-enzymes in the respiratory epithelial cells, and the 
olfactory nerve, providing a pathway for the coronavirus to 
enter the CNS.
Neuronal Pathway
Neurotropic viruses, such as coronaviruses, use sensory and 
motor neuronal pathways to enter the CNS. One example of 
a neuronal pathway is the olfactory nerve (Desforges et  al. 
2019). This is mediated by the unique organization of olfactory 
nerves and the olfactory bulb in the nasal cavity and forebrain. 
The virus thus can reach the brain and CSF, which can cause 
inflammation and a demyelinating reaction. If the infection is 
set, then the viruses can reach the whole brain and CSF in 
less than 7  days (Bohmwald et  al., 2018). Altered olfaction 
and gustatory problems (anosmia, hyposmia, and ageusia) have 
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been reported in 49% of COVID-19 patients (Hornuss et  al., 
2020; Vaira et  al., 2020) implicating the possibility of CNS 
infection through the olfactory neuronal pathway.
ACE2 and Its Role in Neuropsychiatric 
Complications
ACE2 enzyme is widely present in various organs including 
oro-nasal, respiratory, cardiovascular, cerebrovascular, and 
immune systems. The high density of ACE2  in oro-nasal 
mucosa and their binding with SARS-CoV-2 may account 
for olfactory symptoms of anosmia in COVOD-19 (Lechien 
et al., 2020). Coronaviruses directly bind to ACE-2 receptors 
in respiratory epithelial cells cause cytokine storm, which 
causes widespread inflammation in patients with COVID-19, 
leading to multiple organ damage and immune-mediated 
encephalopathy manifesting as delirium and convulsions. 
Neuroinflammation is a well-recognized mechanism for the 
development of psychiatric disorders (Yuan et  al., 2019). It 
can also cause hypercoagulable states causing ischaemic stroke 
besides other vascular events (Fotuhi et  al., 2020). ACE2 
plays an important role in controlling blood pressure but 
binding to SARS-CoV-2 can cause an increase in blood 
pressure, which can increase the propensity to cerebral 
hemorrhage. This may also explain the increase in mortality 
in patients with COVID-19 with comorbid metabolic 
conditions such as hypertension, high body mass index and 
diabetes (Fang et  al., 2020). It has also been proposed that 
the spike protein of SARS-CoV-2 can bind to ACE2 receptors 
in capillaries, breaking the blood-brain barrier and allowing 
the virus to enter the brain directly (Wu et  al., 2020). 
Neurons have a high density of ACE-2 and high binding 
to coronaviruses if they cross the blood-brain barrier. SARS-
CoV-2 can lie latent in the neurons of patients who recover 
from acute effects of COVID-19, increasing the risk of long-
term consequences by causing demyelination and 
neurodegeneration (Lippi et  al., 2020).
NEUROPSYCHIATRIC AND COGNITIVE 
EFFECTS OF CORONAVIRUS INFECTION
Acute Effects
In the short-term, 20–40% of COVID-19 cases may present 
with neuropsychiatric complications, such as cerebrovascular 
events, headache, dizziness, encephalopathies, anosmia, 
ageusia, and mood problems (Bo et  al., 2020; Crunfli et  al., 
2020; Lu et  al., 2020; Mao et  al., 2020; Mirfazeli et  al., 
2020; Troyer et  al., 2020; Varatharaj et  al., 2020; Wu et  al., 
2020; Zhang et  al., 2020), see Table  1. The acute effect of 
CoV infections on the CNS is manifested in viral encephalitis, 
infectious toxic encephalopathy, and acute cerebrovascular 
disease. In a recent meta-analytic review, Rogers et al. (2020) 
reported the neuropsychiatric short- and long-term 
consequences of SARS and MERS infection. They reported 
that during the acute illness, 27–41% of cases had 
neuropsychiatric symptoms such as confusion, depressed 
mood, anxiety, impaired memory, and insomnia. Steroid-
induced mania and psychoses were also reported. The meta-
analysis also looked at the available data related to COVID-19 
infection and neuropsychiatric consequences and found that 
confusion and agitation were present in 65–69% of the 
intensive care unit patients. Importantly, at discharge, 33% 
of the patients with COVID-19 had dysexecutive syndromes. 
Similarly, in a United  Kingdom wide surveillance study, 153 
patients were reported to have neurological and 
neuropsychiatric complications following COVID-19 infection 
(Varatharaj et al., 2020). Twenty-one of these cases developed 
a new diagnosable psychiatric disorder. The other noteworthy 
observation was the effect of age on altered mental status 
and cerebrovascular incident. Thirty-seven patients had altered 
mental status and 49% of these patients were younger than 
60  years. However, of 74 patients who presented with 
cerebrovascular incidents, 81% of the patients were aged 
over 60. In another report, Mao et  al. (2020) reported 
TABLE 1 | Percentage of COVID-19 patients showing neuropsychiatric and cognitive effects.
Reference
COVID-19 patients showing neuropsychiatric and cognitive effects
CNS1 PNS2 Affective disorders Anxiety Fatigue PTSD Impaired attention Impaired memory
Short-term Bo et al., 2020 96%
Crunfli et al., 2020 20% 28% 45% 28%
Lu et al., 2020 25% 35%a 42% 27% 13%
Mao et al., 2020 53% 19%
Mirfazeli et al., 2020 40% 36%b
Varatharaj et al., 2020 62% 17% 26%
Zhang et al., 2020 29%
Long-term Hampshire et al., 2020 0.57SDc
Lu et al., 2020 10% 22% 17% 7% 28%
Woo et al., 2020 11% 17% 44% 50%
1Central nervous system (CNS) includes dizziness, headaches, mental state, ataxia, seizure, and acute cerebrovascular disease.
2Peripheral nervous system (PNS) includes an impaired sense of smell, taste, vision, and nerve pain.
aA count of PNS symptoms occurring, it is possible a single patient had multiple symptoms.
bAverage of reported PNS symptoms.
CSignificant SD away from the healthy control group, indicating cognitive impairments for groups with different levels of medical assistance, the value here is the SD for patients 
requiring hospitalization with a ventilator.
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neurologic manifestations of COVID-19. The study had 214 
patients with mild to severe COVID-19 infection. Around 
36.4% of the patients showed neurologic manifestations 
involving the CNS, peripheral nervous system (PNS) and 
skeletal muscles. These neurologic manifestations were more 
prevalent in patients with a severe infection and included 
signs of impaired consciousness and acute cerebrovascular 
diseases. Autopsy results have indicated degenerated neurons 
and an increased blood flow to some regions together with 
edematous brain tissue (Mao et  al., 2020).
Structural brain abnormalities have also been reported with 
SARS-CoV-1 and MERS infections. In an MRI study looking 
into the post-infectious neurological consequences of MERS 
in three patients with severe neurologic syndrome found 
hyperintensities in the white matter of the parietal lobes, 
temporal lobes, frontal lobes, basal ganglia, and corpus callosum 
(Arabi et  al., 2015). The neurological manifestations shown by 
these patients included: altered mental status (ranging from 
confusion to coma) ataxia, and focal motor deficits. Similarly, 
a study investigating autopsies of six SARS patients found 
evidence of edema and scattered red degeneration of the neurons 
(likely the result of neuronal hypoxia or ischemia), after finding 
evidence of SARS genome sequences in the hypothalamus and 
cortex (Gu et  al., 2005). Structural brain abnormalities have 
been reported in COVID-19 patients too. Montalvan et  al. 
(2020) have reported cases with brain abnormalities present 
in the bilateral thalamic, medial temporal lobes, hippocampus, 
and insular regions.
As reported by Helms et al. (2020), there are some findings 
of encephalopathy and reduced blood flow in the frontotemporal 
brain region following a COVID-19 infection. The extent to 
which COVID-19 infection leads to neurological damages 
and neuronal symptoms is currently still unknown. However, 
several studies have found patients with neurological diseases 
ranging from encephalitis to strokes (Mao et al., 2020; Moriguchi 
et  al., 2020). Encephalitis alone is linked to an increased 
risk of a range of long-term sequelae such as epilepsy, bipolar 
disorders, psychotic disorders, anxiety disorders, cognitive 
problems, and dementia (Granerod et  al., 2017).
Long-Term and Chronic Neuropsychiatric 
Sequelae
It is known that the neural and immune cells can host 
latent CoV which could contribute to delayed neurologic 
and neuropsychiatric complications (Desforges et  al., 2019). 
However, long-term neuropsychiatric sequelae of COVID-19 
are currently unknown. We  can speculate long-term effects 
from our understanding of the mechanisms of the COVID-19 
on the CNS and evidence from long-term neuropsychiatric 
effects of SARS-CoV-1 and MERS. Lam et al. (2009) reported 
that 55% of survivors of SARS-CoV-1 had post-traumatic 
stress disorder (PTSD). Furthermore, depression was in 39%, 
pain disorder in 36.4%, panic disorder in 32.5%, and obsessive-
compulsive disorder in 15.6% of SARS-CoV-1 survivors. In 
their meta-analytic review, Rogers et  al. (2020) also reported 
long-term neuropsychiatric consequences of SARS and MERS 
infections in 10–20% of the cases, such as depressed mood, 
insomnia, anxiety, irritability, memory impairment, and fatigue. 
However, it is important to understand that the neuropsychiatric 
manifestations, such as PTSD, depression, or anxiety, following 
COVID-19 infection could also be  a psychological reaction 
to being infected, being in intensive care unit or experiencing 
stigma of contracting the infection.
If similar proportions of long-term neuropsychiatric 
complications emerge following COVID-19, then we  can 
expect a crashing wave of neuropsychiatric sequelae (Troyer 
et al., 2020), which will have huge implication for management 
of the stretched healthcare resources in every country. Besides 
the neuropsychiatric sequelae, long-term implications will 
be  observed with many neurological problems. For example, 
loss of smell is considered one of the hallmark symptoms 
of COVID-19 infection implying CNS involvement. This 
might have long-term implications for neuro infections and 
neurodegenerative diseases. Indeed, loss of olfaction is 
considered an early manifestation in Parkinson’s disease (Doty, 
2012; Chase and Markopoulou, 2020). Therefore, the emergence 
of cognitive symptoms following COVID-19 may indicate 
an underlying neurodegenerative process. Furthermore, 
individuals with certain immunocompromised neurological 
conditions such as multiple sclerosis (MS) may show alterations 
in their non-motor symptoms following COVID-19, which 
may indicate an underlying neurodegenerative process. Higher 
risk of developing Parkinson’s disease and MS has been 
previously linked to SARS-CoV-1 infection (Fazzini et  al., 
1992; Murray et  al., 1994). Indeed, long-term assessment of 
cognition will become a critical part of the care pathway 
for such individuals.
Long-Term Cognitive Sequelae
From the emerging evidence and our understanding of the 
mechanism of CoV in the CNS, one can expect to have a 
range of cognitive consequences of COVID-19 infection. 
Attention and dysexecutive symptoms have commonly been 
reported with COVID-19 (Rogers et  al., 2020; Varatharaj 
et  al., 2020). Hypoperfusion in the frontotemporal region 
of the brain has also been reported (Helms et  al., 2020) as 
well as structural brain abnormalities thalamic and temporal 
regions (Montalvan et al., 2020). Considering the demyelinating 
nature of the viral infection in the CNS, we  can expect 
common cognitive problems that characterize demyelinating 
illnesses (such as MS). The Symbol Digit Modalities Test 
(SDMT), a test to assess the speed of information processing, 
is an exceptionally reliable and sensitive cognitive test for 
MS patients (Benedict et  al., 2017). Similarly, a link between 
loss of smell in COVID-19 patients and the prodromal phase 
of Parkinson’s disease should be kept in mind while examining 
long-term cognitive consequences. A large amount of research 
has shown that executive functions are primarily affected in 
the prodromal phase of Parkinson’s disease along with 
prominent memory problems (Fengler et  al., 2017). Taken 
together, the long-term cognitive examination of COVID-19 
survivors should at least include tests assessing attention, 
executive functions, learning, and memory as well as the 
speed of information processing.
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Implications for Monitoring Long-Term 
Neuropsychiatric and Cognitive Sequelae
It is clear from the past outbreaks of SARS-CoV-1 and MERS 
and current reports of neurological and neuropsychiatric 
complications following COVID-19 that a large number of 
survivors will experience a range of neuropsychiatric and 
cognitive sequelae. These are likely to affect their mental, 
physical, and cognitive well-being. Which, in turn, will affect 
their emotional, occupational, and financial situations. Some 
of these patients may develop a full-blown neurological or 
psychiatric illness, or some might experience mild cognitive 
problems and that will increase their risk of developing dementia. 
Early indications show that the cognitive domains of executive 
functions, attention, and memory appear to be  affected by 
COVID-19. Furthermore, there are potential increases in affective 
disorders, anxiety, fatigue, and PTSD (Hampshire et  al., 2020; 
Lu et al., 2020; Woo et al., 2020), see Table 1. These symptoms 
can be  due to pathoplastic change in brain physiology where 
the COVID-19 infection may modify brain functions after 
infection, which can lead to the development of brain 
vulnerabilities that may increase the probability to develop 
psychological distress. It is also possible that these 
neuropsychiatric symptoms and disorders are the psychological 
reactions of having contracted COVID-19 and undergoing 
associated medical interventions. This complex nature of 
neuropsychiatric presentations can be  understood through a 
careful study of case history, accompanied by standardized 
neuropsychological assessments. This will help clarify if the 
neuropsychiatric and cognitive problems are a direct consequence 
of structural brain abnormalities or are a psychological reaction 
of the potential physical and the mental stress associated with 
recovering from COVID-19. Therefore, early detection and 
prevention of neuropsychiatric and cognitive problems should 
be the long-term aim of health services and governments across 
the world as this could present as a “third wave” of the pandemic.
CONCLUSION
The short-term neuropsychiatric and cognitive complications 
following COVID-19 are varied and affect a large proportion 
of COVID-19 survivors. In the medium- and long-term period, 
there is going to be  an influx of patients with psychiatric and 
cognitive problems who were otherwise healthy prior to 
COVID-19 infection. Increased neuropsychiatric manifestations 
could be  observed in the form of an increase in cases of 
depression, anxiety, PTSD, and in certain cases severe mental 
illnesses. Cognitive sequelae are also likely to be  varied and 
a detailed cognitive evaluation should be  considered for such 
individuals to monitor the emergence of new neurological 
cases. Robust neuropsychiatric and cognitive monitoring will 
enable health care providers to plan adequate health care 
delivery and allocate resources adequately. Early intervention 
for emerging cognitive problems will be critical for independent 
functioning and improved quality of life for many 
COVID-19 survivors.
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